Arnicare Leg Cramps generics — when can they launch?
Arnicare Leg Cramps (COPPER) · Sebela Womens Hlth · 13 active US patents · 0 expired
Where Arnicare Leg Cramps sits in the generic timeline
Mid-term cliff: earliest active US patent for Arnicare Leg Cramps expires in 2032 (~6 years). Generic developers typically begin ANDA bioequivalence studies 3-4 years ahead of this date. Paragraph IV filings + Hatch-Waxman 30-month stays may shift the effective entry by another 18-36 months.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Formulation — 10 patents
- Method of Use — 3 patents
FDA U-codes carved out by Arnicare Leg Cramps patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-4155 | (no description) |
Sample patent estate
Showing 6 of 13 active US patents. View full estate on the Arnicare Leg Cramps drug page →
-
This patent protects a method for placing a contraceptive device within a uterus without blocking the fallopian tubes.USPTO title: Intrauterine contraceptive device
-
This patent protects an intrauterine contraceptive device with a frame made of a specific metal and a copper component.USPTO title: Intrauterine device with controlled copper ion elution
-
This patent protects a method for placing a contraceptive device within a uterus without blocking the fallopian tubes.USPTO title: Intrauterine contraceptive device
-
This patent protects a method for placing a contraceptive device within a uterus without blocking the fallopian tubes.USPTO title: Intrauterine contraceptive device
-
This patent protects a method for placing a contraceptive device within a uterus without blocking the fallopian tubes.USPTO title: Intrauterine contraceptive device
-
This patent protects an intrauterine contraceptive system with a retrieval thread and insertion device.USPTO title: Intrauterine device with retrieval thread
Sources
- FDA Orange Book — patents listed against Arnicare Leg Cramps (NDA filed 2026)
- Arnicare Leg Cramps drug profile — full patent estate, indications, clinical trials, pricing
- Sebela Womens Hlth patent portfolio
- Patent cliff 2032 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Arnicare Leg Cramps — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →